Sangamo Biosciences, Inc.  

(Public, NASDAQ:SGMO)   Watch this stock  
Find more results for SGMO
+0.08 (0.44%)
Mar 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.81 - 18.88
52 week 9.39 - 24.69
Open 18.10
Vol / Avg. 0.00/937,799.00
Mkt cap 1.25B
P/E     -
Div/yield     -
EPS -0.40
Shares 69.06M
Beta 2.13
Inst. own 76%
May 4, 2015
Q1 2015 Sangamo BioSciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 4, 2015
Sangamo BioSciences Inc at Cowen Health Care Conference
Feb 12, 2015
Sangamo BioSciences Inc at Leerink Global Healthcare Conference
Feb 10, 2015
Q4 2014 Sangamo BioSciences Inc Earnings Call - Webcast
Feb 10, 2015
Q4 2014 Sangamo BioSciences Inc Earnings Release
Jan 12, 2015
Sangamo BioSciences Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -28.89% -57.59%
Operating margin -29.89% -58.38%
EBITD margin - -57.19%
Return on average assets -7.06% -13.76%
Return on average equity -8.31% -16.09%
Employees 102 -
CDP Score - -


501 Canal Blvd
RICHMOND, CA 94804-3559
United States - Map
+1-510-9706000 (Phone)
+1-510-2368951 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Sangamo BioSciences, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of zinc finger deoxyribonucleic acid (DNA)-binding proteins (ZFPs), a naturally occurring class of proteins. ZFPs can be engineered to make ZFP nucleases (ZFNs), proteins that can be used to modify DNA sequences in a variety of ways and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. The main focus for its Company is the development of human therapeutics and it is building a pipeline of ZFP Therapeutics. Its lead ZFP Therapeutic, SB-728-T, a ZFN-modified autologous T-cell product for the treatment of human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), is the first therapeutic application of its ZFN technology and is being evaluated in an ongoing Phase 11 and two Phase I/II clinical trials. In October 2013, Sangamo BioSciences Inc acquired Ceregene Inc.

Officers and directors

Bill R. Ringo Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Edward O. Lanphier II President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
H. Ward Wolff Chief Financial Officer, Principal Financial and Accounting Officer, Executive Vice President
Age: 65
Bio & Compensation  - Reuters
Geoffrey M. Nichol Executive Vice President - Research and Development
Age: 59
Bio & Compensation  - Reuters
Philip D. Gregory Ph.D. Senior Vice President - Research, Chief Scientific Officer
Age: 43
Bio & Compensation  - Reuters
Dale G. Ando M.D. Vice President - Therapeutic Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
H. Stewart Parker Director
Age: 58
Bio & Compensation  - Reuters
Paul B. Cleveland Independent Director
Age: 57
Bio & Compensation  - Reuters
Stephen G. Dilly Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
John W. Larson Independent Director
Age: 78
Bio & Compensation  - Reuters